CSTL
Castle Biosciences Inc
35.20$
+0.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.0% | +1.1% | +6.3% | +5.6% | +3.2% | -5.6% | +8.6% | +3.3% | +2.8% | -5.3% | +2.4% | |
| – | +5.7% | +0.0% | +8.3% | +7.6% | +4.5% | -3.0% | -0.2% | +2.6% | +1.0% | -8.9% | +3.7% | |
| – | +8.4% | -16.1% | +3.2% | +11.0% | +26.1% | -25.1% | -8.3% | +4.0% | +36.4% | -45.4% | -2.6% | |
| – | +5.8% | -1.6% | +8.6% | +7.7% | +4.8% | -6.1% | +0.3% | +4.2% | +4.2% | -12.6% | +2.0% | |
| – | +3.5% | +11.5% | +7.7% | +9.3% | +1.9% | +10.0% | -7.2% | -5.4% | -12.3% | -2.6% | +14.4% | |
| – | +37.7% | -3.7% | +4.8% | -18.0% | +23.8% | -15.8% | +22.1% | +3.4% | +18.5% | +2.0% | +1.1% | |
| – | -0.1% | +0.1% | +0.0% | +0.0% | -0.1% | +0.0% | +0.0% | 0.0% | +0.0% | +0.1% | +0.0% | |
| – | -2.1% | -2.1% | -2.2% | -2.2% | -4.3% | -29.6% | +39.0% | -2.4% | -2.5% | -2.5% | -2.6% | |
| – | +23.6% | -9.7% | +13.2% | +15.9% | +2.6% | -18.6% | +45.5% | +7.1% | +12.5% | -19.8% | +5.5% | |
| – | +31.2% | -33.0% | +23.5% | +12.3% | +11.5% | -24.5% | +36.5% | +8.7% | +24.2% | -29.0% | +15.9% | |
| – | +4.2% | +4.6% | +3.1% | +42.3% | +11.3% | +31.0% | +38.1% | -58.8% | +20.2% | +67.7% | +48.4% | |
| – | +48.2% | -9.3% | +2.4% | -28.6% | +1.3% | +23.2% | +55.0% | -7.4% | +53.2% | -19.6% | -35.7% | |
| – | – | – | +0.1% | +0.1% | -2.7% | -8.5% | -9.2% | +24.1% | -4.1% | -12.9% | -14.8% | |
| – | +1.4% | +2.9% | +5.3% | +4.0% | +3.4% | -3.4% | +3.4% | +2.6% | +0.8% | -2.0% | +1.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.2% | +1.3% | +4.6% | +2.3% | +2.7% | -5.3% | +3.3% | -1.6% | +0.9% | +1.9% | +1.7% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.